Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 EV-to-EBIT is 142.14 as of Jul. 16, 2026. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.74 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, CanSino Biologics ranks worse than 96.07% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CanSino Biologics's Enterprise Value for the quarter that ended in Dec. 2025 was $982.02 Mil.
CanSino Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics EV-to-EBIT Related Terms
CanSino Biologics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's EV-to-EBIT falls into.
CanSino Biologics's current Enterprise Value is $1,108.30 Mil.
CanSino Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (CASBF) has a EV-to-EBIT of 142.14 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #660 out of 687 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is CanSino Biologics' EV-to-EBIT too high?
CanSino Biologics' current EV-to-EBIT is 142.14. The Drug Manufacturers industry median EV-to-EBIT is 15.86. CanSino Biologics' value of 142.14 is 796.2% above this industry median. Based on the distribution chart, CanSino Biologics ranks #660 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #660 out of 687 companies for EV-to-EBIT. This places CanSino Biologics in the lower half of its industry. The industry median EV-to-EBIT is 15.86. CanSino Biologics' value of 142.14 is 796.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current EV-to-EBIT of 142.14 is 796.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current EV-to-EBIT is 142.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.74, compared to a current price of $2.60 — trading 70.3% below its estimated fair value. The current EV-to-EBIT is 142.14 and 796.2% above the Drug Manufacturers industry median of 15.86. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current EV-to-EBIT is 142.14 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.3% below its estimated GF Value™ of $8.74.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
EV-to-EBIT: 142.14
GF Value™: $8.74 vs. price of $2.60 (70.3% below fair value)
Industry Position: 796.2% above the Drug Manufacturers median (#660 of 687)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
